Citations

Showing 10 of 108094 citations.

Association of Early and Late Hospital Readmissions with a Novel Housing-Based Socioeconomic Measure
Zurek, Kaitlyn I. , Boswell, Christopher L. , Miller, Nathanial E., Pecina, Jennifer L. , Decker, Matthew , Wi, Chung I., Garrison, Gregory M. , E Miller, Nathanial, L Pecina, Jennifer, I Wi, Chung, Pecina, Jennifer , Decker, Matthew D., Wi, Chung‐Il

Mayo Clinic

Health Services Research and Managerial Epidemiology | June 23, 2022 | Volume: 9 | Issue: No issue available | Pages: No page available

10.1177/23333928221104644 | PMID 35769114 Get It

Background While socioeconomic status has been linked to hospital readmissions for several conditions, reliable measures of individual socioeconomic status are often not available. HOUSES, a new measure of individual socioeconomic status based upon objective public data about one's housing unit, is inversely associated with overall hospitalization rate but it has not been studied with respect to readmissions. Purpose To determine if patients in the lowest HOUSES quartile are more likely to be readmitted within 30 days (short-term) and 180 days (long-term). Methods A retrospective cohort study of 11 993 patients having 21 633 admissions was conducted using generalized linear mixed-effects models. Results HOUSES quartile did not show any significant association with early readmission. However, when compared to the lowest HOUSES quartile, the second quartile (OR = 0.90, 95%CI 0.83-0.98) and the third quartile (OR = 0.91, 95%CI 0.83-0.99) were associated with lower odds of late readmission while the highest quartile (OR = 0.91, 95%CI 0.82-1.01) was not statistically different. Conclusion HOUSES was associated with late readmission, but not early readmission. This may be because early readmissions are influenced by medical conditions and hospital care while late readmissions are influenced by ambulatory care and home-based factors. Since HOUSES relies on public county assessor data, it is generally available and may be used to focus interventions on those at highest risk for late readmission.
Agency in physiological dynamics
Rogers, James R. , Gallaher, Edward J., Dingli, David

Mayo Clinic

System Dynamics Review | June 23, 2022 | Volume: 38 | Issue: 2 | Pages: 169-189

10.1002/sdr.1713 Get It

AbstractWith a view to finding new applications of biomedical system dynamics, this article expands upon on our talk at the 2021 International System Dynamics Conference on the occasion of receiving the J. W. Forrester Award for the article, “Personalized ESA doses for anemia management in hemodialysis patients with end‐stage renal disease” (System Dynamics Review 2018, 34(1–2): 121–153). We summarize the evolution of a project which took place in a clinical setting between 2008 and 2015 that led to the award‐winning article. We present concepts from receptor theory that informed the first system dynamics application of biophysical system dynamics to the successful diagnosis, prescription, administration, and improvement of individualized patient care. We expand upon these ideas to present a generalized structure, DART (Dynamic Approach to Receptor Theory). It can be used to simulate the physiological effects of any agent, be it an exogenous pharmacological agent, an endogenous enzyme or hormone, or a toxin of some sort. We suggest including within the pharmacological technical literature easily acquired but frequently omitted critical parameter values and rate constants. These would enable researchers to perform transient analyses of biophysical phenomena in addition to static equilibrium analyses typically performed. With the availability of this data, we suggest that the fundamental tools of system dynamics might be used to reconceptualize the 100‐year‐old field of “occupation theory” (today, receptor theory) to deliver high‐resolution insights into physiological dynamics and the preventive, prescriptive, and palliative interventions they might require. It is our hope that these ideas could pave the way forward to novel, groundbreaking applications in biomedical system dynamics. © 2022 System Dynamics Society.
GAN augmentation for multiclass image classification using hemorrhage detection as a case-study
Jeong, Jiwoong , Patel, Bhavik N. , Banerjee, Imon , Patel, Bhavik, Banerjee, Imon

Mayo Clinic

Journal of Medical Imaging | June 23, 2022 | Volume: 9 | Issue: 03 | Pages: No page available

10.1117/1.jmi.9.3.035504 | PMID 35769344 Get It

IFT80 negatively regulates osteoclast differentiation via association with Cbl-b to disrupt TRAF6 stabilization and activation
Deepak, Vishwa , Yang, Shuting , Li, Ziqing , Li, Xinhua , Ng, Andrew , Xu, Ding , Li, Yiping , Oursler, Merry Jo, Yang, Shuying , Yang, Shuying

Mayo Clinic

Proceedings of the National Academy of Sciences | June 23, 2022 | Volume: 119 | Issue: 26 | Pages: No page available

10.1073/pnas.2201490119 | PMID 35733270 Get It

Excess bone loss due to increased osteoclastogenesis is a significant clinical problem. Intraflagellar transport (IFT) proteins have been reported to regulate cell growth and differentiation. The role of IFT80, an IFT complex B protein, in osteoclasts (OCs) is completely unknown. Here, we demonstrate that deletion of IFT80 in the myeloid lineage led to increased OC formation and activity accompanied by severe bone loss in mice. IFT80 regulated OC formation by associating with Casitas B-lineage lymphoma proto-oncogene-b (Cbl-b) to promote protein stabilization and proteasomal degradation of tumor necrosis factor (TNF) receptor–associated factor 6 (TRAF6). IFT80 knockdown resulted in increased ubiquitination of Cbl-b and higher TRAF6 levels, thereby hyperactivating the receptor activator of nuclear factor-κβ (NF-κβ) ligand (RANKL) signaling axis and increased OC formation. Ectopic overexpression of IFT80 rescued osteolysis in a calvarial model of bone loss. We have thus identified a negative function of IFT80 in OCs.
Associations of Vascular Risk and Amyloid Burden with Subsequent Dementia
Wu, Aozhou , Knopman, David S. , Rahmim, Arman , Sharrett, A. Richey , Spira, Adam P. , Wong, Dean F. , Wagenknecht, Lynne E. , Hughes, Timothy M. , Knopman, David S. , Gottesman, Rebecca F , Gottesman, Rebecca F. , Coresh, Josef , Jack, Clifford R. , Walker, Keenan A. , Mosley, Thomas H.

Mayo Clinic

Annals of Neurology | June 22, 2022 | Volume: 92 | Issue: 4 | Pages: 607-619

10.1002/ana.26447 | PMID 35732594 Get It

Objective Midlife vascular risk factors (MVRFs) are associated with incident dementia, as are amyloid β (Aβ) deposition and neurodegeneration. Whether vascular and Alzheimer disease‐associated factors contribute to dementia independently or interact synergistically to reduce cognition is poorly understood. Methods Participants in the Atherosclerosis Risk in Communities–Positron Emission Tomography study were followed from 1987–1989 (45–64 years old) through 2016–2017 (74–94 years old), with repeat cognitive assessment and dementia adjudication. In 2011–2013, dementia‐free participants underwent brain magnetic resonance imaging (with white matter hyperintensity [WMH] and brain volume measurement) and florbetapir (Aβ) positron emission tomography. The relative contributions of vascular risk and injury (MVRFs, WMH volume), elevated Aβ standardized uptake value ratio (SUVR), and neurodegeneration (smaller temporoparietal brain regions) to incident dementia were evaluated with adjusted Cox models. Results In 298 individuals, 36 developed dementia (median follow‐up = 4.9 years). Midlife hypertension and Aβ each independently predicted dementia risk (hypertension: hazard ratio [HR] = 2.57, 95% confidence interval [CI] = 1.16–5.67; Aβ SUVR [per standard deviation (SD)]: HR = 2.57, 95% CI = 1.72–3.84), but did not interact significantly, whereas late life diabetes (HR = 2.50, 95% CI = 1.18–5.28) and Aβ independently predicted dementia risk. WMHs (per SD: HR = 1.51, 95% CI = 1.03–2.20) and Aβ SUVR (HR = 2.52, 95% CI = 1.83–3.47) independently contributed to incident dementia, but WMHs lost significance when MVRFs were included. Smaller temporoparietal brain regions were associated with incident dementia, independent of Aβ and MVRFs (HR = 2.18, 95% CI = 1.18–4.01). Interpretation Midlife hypertension and late life Aβ are independently associated with dementia risk, without evidence for synergy on a multiplicative scale. Given the independent contributions of vascular and amyloid mechanisms, multiple pathways should be considered when evaluating interventions to reduce the burden of dementia. ANN NEUROL 2022;92:607–619
Joint Final Report of EORTC 26951 and RTOG 9402: Phase III Trials With Procarbazine, Lomustine, and Vincristine Chemotherapy for Anaplastic Oligodendroglial Tumors
Lassman, Andrew B. , Hoang‐Xuan, Khê , Polley, Mei‐Yin C. , Cairncross, J. Gregory , Ashby, Lynn S., Taphoorn, Martin , Souhami, Luís, Dinjens, Winand N.M. , Kouwenhoven, Mathilde C.M. , Fink, Karen, French, Pim J. , Macdonald, David R., Lacombe, Denis , Won, Minhee , Gorlia, Thierry, Bent, Martin J. van den , Taphoorn, Martin J B , Dinjens, Winand N M , Laack, Nadia N Issa , Kouwenhoven, Mathilde C M , French, Pim J , Mehta, Minesh P , van den Bent, Martin J , Brandes, Alba Ariela , Kros, Johan M. , Laack, Nadia N. , Mehta, Minesh P.

Mayo Clinic

Journal of Clinical Oncology | June 22, 2022 | Volume: 40 | Issue: 23 | Pages: 2539-2545

10.1200/jco.21.02543 | PMID 35731991 Get It

Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the basis of the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported. Anaplastic oligodendroglial tumors (AOTs) are chemotherapy-sensitive brain tumors. We report the final very long-term survival results from European Organization for the Research and Treatment of Cancer 26951 and Radiation Therapy Oncology Group 9402 phase III trials initiated in 1990s, which both studied radiotherapy with/without neo/adjuvant procarbazine, lomustine, and vincristine (PCV) for newly diagnosed anaplastic oligodendroglial tumors. The median follow-up duration in both was 18-19 years. For European Organization for the Research and Treatment of Cancer 26951, median, 14-year, and probable 20-year overall survival rates without versus with PCV were 2.6 years, 13.4%, and 10.1% versus 3.5 years, 25.1%, and 16.8% (N = 368 overall; hazard ratio [HR] 0.78; 95% CI, 0.63 to 0.98; P = .033), with 1p19q codeletion 9.3 years, 26.2%, and 13.6% versus 14.2 years, 51.0%, and 37.1% (n = 80; HR 0.60; 95% CI, 0.35 to 1.03; P = .063), respectively. For Radiation Therapy Oncology Group 9402, analogous results were 4.8 years, 16.5%, and 11.2% versus 4.8 years, 29.1%, and 24.6% (N = 289 overall; HR 0.79; 95% CI, 0.61 to 1.03; P = .08), with codeletion 7.3 years, 25.0%, and 14.9% versus 13.2 years, 46.1%, and 37% (n = 125; HR 0.61; 95% CI, 0.40 to 0.94; P = .02), respectively. With that, the studies show similar long-term survival even without tumor recurrence in a significant proportion of patients after first-line treatment with radiotherapy/PCV.
Detection of Anal Intraepithelial Neoplasia and Anal Squamous Cell Carcinoma on Colonoscopy
Voss, Jordan K. , Kurdi, Ahmed T. , Neto, Manuel B. Braga , Chedid, Victor , Neto, Manuel Braga, Chedid, Victor G , Braga Neto, Manuel B , Wang, Xiao‐Jing

Mayo Clinic

ACG Case Reports Journal | June 22, 2022 | Volume: 9 | Issue: 6 | Pages: e00792

10.14309/crj.0000000000000792 | PMID 35756724 Get It

ABSTRACT The purpose of this case series is to review the endoscopic detection of anal intraepithelial neoplasia and anal squamous cell carcinoma including the role of rectal retroflexion and narrow-band imaging. Four cases of anal intraepithelial neoplasia were incidentally discovered in women aged 55–71 years. Anal lesions identified included sessile polyps, nodular mucosa, and circumferential polyps. A fifth patient, who presented with abdominal pain, was found to have a 3 cm anal squamous cell carcinoma on diagnostic colonoscopy, despite a negative colonoscopy 21 months earlier. In the absence of contraindications, retroflexion should be performed on all patients. Suspicious anal mucosa warrants biopsy.
Diagnosis of coexistent neurodegenerative dementias in multiple sclerosis
Londoño, Diana, Arumaithurai, Kogulavadanan , Constantopoulos, Eleni , Basso, Michael R. , Reichard, R. Ross , Keegan, B. Mark , Londoño, Diana P, Keegan, B Mark , Flanagan, Eoin P.

Mayo Clinic

Brain Communications | June 22, 2022 | Volume: 4 | Issue: 4 | Pages: No page available

10.1093/braincomms/fcac167 | PMID 35822102 Get It

Abstract Among people with multiple sclerosis, cognitive impairment occurs commonly and is a potent predictor of disability. Some multiple sclerosis patients present with severe cognitive impairment, and distinguishing multiple sclerosis-related cognitive impairment from co-existent progressive neurodegenerative diseases such as Alzheimer disease poses a diagnostic challenge. The use of biomarkers such as PET and CSF proteins may facilitate this distinction. The study was a retrospective, descriptive study on convenience samples of separate cohorts, one of cognitively impaired multiple sclerosis patients evaluated on autopsy to demonstrate coincidence of both multiple sclerosis and neurodegenerative cognitive diseases. The second cohort were cognitively impaired multiple sclerosis patients evaluated by biomarker to investigate possible additional neurodegenerative cognitive disorders contributing to the cognitive impairment. We investigated selected biomarkers among 31 severely impaired patients (biomarker cohort) and 12 severely impaired patients assessed at autopsy and selected 24 (23 biomarker cohort, 1 autopsy cohort) had comprehensive neurocognitive testing. Biomarker cohort investigations included 18F-Fluorodeoxyglucose PET and/or CSF amyloid Aβ1-42, phospho-tau and total tau levels. The autopsy cohort was evaluated with comprehensive neuropathological assessment for aetiology of cognitive impairment. The cohorts shared similar sex, age at multiple sclerosis onset and multiple sclerosis clinical course. The autopsy-cohort patients were older at diagnosis (69.5 versus 57 years, P = 0.006), had longer disease duration [median (range) 20 years (3–59) versus 9 (1–32), P = 0.001] and had more impaired bedside mental status scores at last follow-up [Kokmen median (range) 23 (1–38) versus 31 (9–34) P = 0.01]. Autopsy-cohort patients confirmed, or excluded, coexistent neurogenerative disease by neuropathology gold standard. Most biomarker-cohort patients had informative results evaluating coexistent neurogenerative disease. Biomarkers may be useful in indicating a coexistent neurodegenerative disease earlier, and in life, in patients with multiple sclerosis and significant cognitive impairment.
Globally accessible end-user-friendly prostate cancer risk prediction tools based on contemporary cohorts with heterogeneous missing risk factors
Neumair, Matthias, Freedland, Stephen J. , Haese, Alexander , Guerrios‐Rivera, Lourdes , Boorjian, Stephen A. , Poyet, Cédric , Herkommer, Kathleen , Meissner, Valentin H. , Kattan, Michael W. , Hoedt, Amanda M. De , Liss, Michael A. , Leach, Robin J. , Cooperberg, Matthew R , Saba, Karim , Vickers, Andrew J , Ankerst, Donna P.

Mayo Clinic

No container title available | June 22, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-1716616/v1 Get It

Abstract Background: Missing risk factors, whether random or not measured at all, across different hospitals and patients provide challenges, both for the developers of online clinical risk tools and the patients trying to use such tools. This paper provides a development and end-user solution to the commonly encountered limitations of clinical risk tool based decision making due to missing information.Methods: Six state-of-the-art logistic regression approaches accommodating missing data were compared using prostate cancer data from ten North American and European cohorts from the Prostate Biopsy Collaborative Group (PBCG). An additional large European PBCG cohort was withheld for external validation, where calibration-in-the-large (CIL), calibration curves, and area-underneath-the-receiver-operating characteristic curve (AUC) were evaluated. Ten-fold leave-one-cohort-internal validation further validated the optimal missing data approach.Results: Among 12,703 biopsies from 10 training cohorts, 3,597 (28%) had clinically significant prostate cancer, compared to 1,757 of 5,540 (32%) in the external validation cohort. In external validation, the available cases method that pooled individual patient data containing all risk factors input by an end-user had best CIL, under-predicting risks as percentages by 2.9% on average, and obtained an AUC of 75.7%. Imputation had the worst CIL (-13.3%). The available cases method was further validated as optimal in internal cross-validation and thus used for development of an online risk tool. For end-users of the risk tool, two risk factors were mandatory: serum prostate-specific antigen (PSA) and age, and ten were optional: digital rectal exam, prostate volume, prior negative biopsy, 5-alpha-reductase-inhibitor use, prior PSA screen, African ancestry, Hispanic ethnicity, first-degree prostate-, breast-, and second-degree prostate-cancer family history.Conclusion: Developers of clinical risk prediction tools should optimize use of available data and sources even in the presence of high amounts of missing data and offer options for users with missing risk factors.
Genome-wide methylation profiling reveals differentially methylated genes in blood DNA of small-cell lung cancer patients
He, Yanqi , Wei, Calvin R. , Cunningham, Julie M. , Yang, Ping , Wei, Calvin, Sun, Zhifu , Wang, Liang , Wei, Zong

Mayo Clinic

Precision Clinical Medicine | June 22, 2022 | Volume: 5 | Issue: 3 | Pages: No page available

10.1093/pcmedi/pbac017 | PMID 35875603 Get It